Interferon alpha for the treatment of advanced renal cancer.
This paper is an overview on the place of IFN-alpha in metastatic renal cell carcinoma (MRCC). After a presentation of MRCC and the mode of action of IFN-alpha, the results of studies including IFN-alpha alone or in combination with IL-2, chemotherapy and other biological modifiers are presented. Finally, new trends for new drugs, including antiangiogenic therapies, are discussed.
Ravaud
Alain
A
Department of Medical Oncology and Radiotherapy, Hôpital Saint-André, 1 rue Jean Burguet, 33075 Bordeaux cedex, France. alain.ravaud@chu-bordeaux.fr
Dilhuydy
Marie-Sarah
MS
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000098:blood supply / Q000601:surgery / Q000628:therapy*; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic / Q000628:therapy; D016032:Randomized Controlled Trials as Topic
D020533:Angiogenesis Inhibitors; D000964:Antimetabolites, Antineoplastic; D016898:Interferon-alpha; D007376:Interleukin-2; D005472:Fluorouracil